AU2001275959A1 - Method of treating the syndrome of type 2 diabetes in humans - Google Patents

Method of treating the syndrome of type 2 diabetes in humans

Info

Publication number
AU2001275959A1
AU2001275959A1 AU2001275959A AU7595901A AU2001275959A1 AU 2001275959 A1 AU2001275959 A1 AU 2001275959A1 AU 2001275959 A AU2001275959 A AU 2001275959A AU 7595901 A AU7595901 A AU 7595901A AU 2001275959 A1 AU2001275959 A1 AU 2001275959A1
Authority
AU
Australia
Prior art keywords
diabetes
syndrome
humans
treating
type
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001275959A
Inventor
Anton H. Clemens
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
CPD LLC
Original Assignee
CPD LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by CPD LLC filed Critical CPD LLC
Publication of AU2001275959A1 publication Critical patent/AU2001275959A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4468—Non condensed piperidines, e.g. piperocaine having a nitrogen directly attached in position 4, e.g. clebopride, fentanyl
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/451—Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU2001275959A 2000-08-15 2001-07-17 Method of treating the syndrome of type 2 diabetes in humans Abandoned AU2001275959A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US63893000A 2000-08-15 2000-08-15
US09/638,930 2000-08-15
PCT/US2001/022466 WO2002013759A2 (en) 2000-08-15 2001-07-17 Method of treating the syndrome of type 2 diabetes in humans

Publications (1)

Publication Number Publication Date
AU2001275959A1 true AU2001275959A1 (en) 2002-02-25

Family

ID=24562030

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001275959A Abandoned AU2001275959A1 (en) 2000-08-15 2001-07-17 Method of treating the syndrome of type 2 diabetes in humans

Country Status (3)

Country Link
EP (1) EP1365756A2 (en)
AU (1) AU2001275959A1 (en)
WO (1) WO2002013759A2 (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100469500B1 (en) 2002-06-29 2005-02-02 엘지전자 주식회사 Tranceiver appratus for mobile communication terminal
JP5128578B2 (en) 2006-04-04 2013-01-23 エモディス ゲーエムベーハー Use of κ-opioid receptor antagonist-containing compositions for the treatment of dissociative disorders
SI2724722T1 (en) * 2006-10-20 2017-07-31 Neurendo Pharma, Llc Method of restoring the incretin effect
ES2629185T3 (en) 2011-08-26 2017-08-07 Deutsche Diabetes-Forschungsgesellschaft e. V. Morphinan derivatives for the treatment of diabetes and related disorders
EP2561866A1 (en) * 2011-08-26 2013-02-27 Heinrich-Heine-Universität Düsseldorf Morphinan-derivatives for treating diabetes and related disorders
CN107405343A (en) 2014-11-07 2017-11-28 明尼苏达大学董事会 Salt and composition available for treatment disease

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU3809999A (en) * 1998-05-18 1999-12-06 Novo Nordisk A/S Novel 1,3,8-triazaspiro[4.5]decanones with high affinity for opioid receptor subtypes

Also Published As

Publication number Publication date
WO2002013759A2 (en) 2002-02-21
WO2002013759A3 (en) 2003-07-10
EP1365756A2 (en) 2003-12-03

Similar Documents

Publication Publication Date Title
AU2001276952A1 (en) Method of treating the syndrome of coronary heart disease risk factors in humans
AU2001256755A1 (en) Biosensor and method for manufacturing the same
AU2001249881A1 (en) Method of treating the heart
AU2002215230A1 (en) Internet commerce system and the method
AU2001262723A1 (en) 1,2-dihydropyridine compounds, process for preparation of the same and use thereof
AU2002219945A1 (en) Composition and method for treating snoring
AU5294100A (en) Method and compositions for treating the inflammatory response
AU2002232479A1 (en) Low-fat nut spread composition and process for making the same
AU4288100A (en) Drying device and method for producing the same
AU2002219002A1 (en) Method and device for treating the surfaces of items
AU2001276295A1 (en) Electric component, method for the production thereof, and its use
AU2002231095A1 (en) Method and composition for the treatment of diabetic neuropathy
AU1359801A (en) Methods and compositions for treating reward deficiency syndrome
EP1217051A3 (en) Surface treating agent for ligneous floorings and process for manufacturing the same
AU1468601A (en) Sorbent, method of making the sorbent, and method of using the sorbent in fixed bed applications
AU2001233932A1 (en) Method and composition
AU2001275959A1 (en) Method of treating the syndrome of type 2 diabetes in humans
MXPA03004017A (en) Method for the treatment of inflammation.
HUP0401577A3 (en) Process for the preparation of 2,4-didezoxyhexoses and 2,4,6-tridezoxyhexoses
AU4198899A (en) Stabilized composition based on pyridinyl-sulfinyl-benzimidazoles and process
AU2002239775A1 (en) Chemical-library composition and method
AU2002315032A1 (en) Improved method of treating the syndrome of type 2 diabetes in humans
AU2001282663A1 (en) Composition comprising chromium picolinate, method of preparing the same and usethereof
AU2001257467A1 (en) Footwear structure and method of forming the same
AU2002256967A1 (en) Treating or reducing the risk of cardiovascular disease